SCHEMBL12428932

SCHEMBL12428932

Cc1cc2c(cc1N)N(C)CCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 6/20 0.45
GAA P10253 3/20 0.45
HPGD P15428 2/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 3/20 0.35
GLA P06280 1/20 0.35
CASP1 P29466 1/20 0.35
TNKS O95271 2/20 0.35
PARP1 P09874 2/20 0.35
TNKS2 Q9H2K2 2/20 0.35
WDR5 P61964 1/20 0.35
ATAD2 Q6PL18 1/20 0.34
PKM P14618 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24405342 0.93 HSD17B10 (0.50) HSD17B10ALDH1A1GAAHPGDMEN1
SCHEMBL15628980 0.85 ALDH1A1 (0.50) HSD17B10ALDH1A1GAAHPGDMEN1
SCHEMBL30896337 0.84 ALDH1A1 (0.44) HSD17B10ALDH1A1GAAHPGDMEN1
SCHEMBL5023388 0.76 ALDH1A1 (0.43) HSD17B10ALDH1A1GAAHPGDMEN1
SCHEMBL22476657 0.75 ALDH1A1 (0.42) HSD17B10ALDH1A1GAAHPGDMEN1
SCHEMBL25558931 0.74 HSD17B10 (0.45) HSD17B10
SCHEMBL520908 0.73 BRD4 (0.51) ALDH1A1GAAHPGDMEN1MAPT
SCHEMBL1453685 0.73 ALDH1A1 (0.58) HSD17B10ALDH1A1GAAHPGDMEN1
SCHEMBL30464716 0.73 ALDH1A1 (0.58) HSD17B10ALDH1A1GAAHPGDMEN1
SCHEMBL16687894 0.72 AR (0.41) HSD17B10ALDH1A1GAAHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981903-B2 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer GLAXOSMITHKLINE LLC (US) 2011-07-19 US disclosed